TITLE

Notice to Readers: Requirements for Use of a New International Certificate of Vaccination or Prophylaxis for Yellow Fever Vaccine

PUB. DATE
April 2008
SOURCE
JAMA: Journal of the American Medical Association;4/23/2008, Vol. 299 Issue 16, p1894
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that the International Certificate of Vaccination or Prophylaxis (ICVP) is required for yellow fever vaccine administered beginning December 15, 2007 under the International Health Regulations (IHR) for entry into certain countries. Persons who are vaccinated for yellow fever before this date can use an old certificate until it expires 10 years after the date of vaccination. The updated ICVPs are available to health care providers for order online through the U.S. Government Printing Office web site.
ACCESSION #
31759373

 

Related Articles

  • Yellow Fever Initiative. Stephenson, Joan // JAMA: Journal of the American Medical Association;6/20/2007, Vol. 297 Issue 23, p2578 

    This article reports on the Yellow Fever Initiative from the World Health Organization. Funded by the Global Alliance for Vaccines and Immunization, the program will set up comprehensive immunization campaigns in a dozen West African countries such as Benin, Burkina Faso, Cameroon, Ghana. The...

  • Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015. Staples, J. Erin; Bocchini Jr., Joseph A.; Rubin, Lorry; Fischer, Marc // MMWR: Morbidity & Mortality Weekly Report;6/19/2015, Vol. 64 Issue 23, p647 

    The article presents doses for yellow fever vaccine as recommended by health experts group U.S. Advisory Committee on Immunization Practices in 2015. Topics discussed include yellow fever risk and epidemiology in travin 2015. Topics discussed include yellow fever risk and epidemiology in...

  • Capacity-building efforts by the AFHSC-GEIS program. Sanchez, Jose L.; Johns, Matthew C.; Burke, Ronald L.; Vest, Kelly G.; Fukuda, Mark M.; In-Kyu Yoon; Lon, Chanthap; Quintana, Miguel; Schnabel, David C.; Pimentel, Guillermo; Mansour, Moustafa; Tobias, Steven; Montgomery, Joel M.; Gray, Gregory C.; Saylors, Karen; Ndip, Lucy M.; Lewis, Sheri; Blair, Patrick J.; Sjoberg, Paul A.; Kuschner, Robert A. // BMC Public Health;2011 Supplement 2, Vol. 11 Issue Suppl 2, p1 

    Capacity-building initiatives related to public health are defined as developing laboratory infrastructure, strengthening host-country disease surveillance initiatives, transferring technical expertise and training personnel. These initiatives represented a major piece of the Armed Forces Health...

  • Training initiatives within the AFHSC-Global Emerging Infections Surveillance and Response System: support for IHR (2005). Otto, Jean L.; Baliga, Priya; Sanchez, Jose L.; Johns, Matthew C.; Gray, Gregory C.; Grieco, John; Lescano, Andres G.; Mothershead, Jerry L.; Wagar, Eric J.; Blazes, David L.; Byarugaba, Denis; Coldren, Rodney; Brown, Matthew; Cooper, Michael; Ducate, Mariette; Espinosa, Benjamin; Ewings, Peerach; Guerrero, Alicia; Hawksworth, Tony; Jackson, Christina // BMC Public Health;2011 Supplement 2, Vol. 11 Issue Suppl 2, p1 

    Training is a key component of building capacity for public health surveillance and response, but has often been difficult to quantify. During fiscal 2009, the Armed Forces Health Surveillance Center, Division of Global Emerging Infections Surveillance and Response System (AFHSC-GEIS) supported...

  • Yellow fever vaccine.  // WHO Technical Report Series;2004, Issue 927, p18 

    The article reports the World Health Organization (WHO) Expert Committee has been informed on the use of mouse LD50 assays in determining the yellow fever vaccines. Identification of the relationship between mouse LD50 units and plaque forming units in each laboratory is a prerequisite in WHO...

  • yellow fever vaccine.  // Royal Society of Medicine: Medicines;2002, p573 

    This article presents information on yellow fever vaccine. This vaccine is used for immunization that consists of a protein suspension containing live, but weakened, yellow fever viruses that are cultured in chick embryos. Immunity lasts for at least ten years. The disease is still prevalent in...

  • Yellow fever in Africa and South America, 2007.  // Weekly Epidemiological Record;3/27/2009, Vol. 84 Issue 13, p97 

    The article focuses on the cases of yellow fever in Africa and South America in 2007. It says that 59 cases of laboratory-confirmed yellow fevers are reported to the World Health Organization (WHO) including the death of 41 people. In 2006, the Yellow Fever Initiative was launched to fight the...

  • Yellow-fever vaccinating centres.  // Weekly Epidemiological Record;5/10/2002, Vol. 77 Issue 19, p163 

    Lists the approved yellow fever vaccines producers for 2002.

  • Yellow Fever Vaccine.  // Annals of Internal Medicine;Aug69, Vol. 71 Issue 2, p365 

    Reports on recommendation of the U.S. Public Health Service Advisory Committee on Immunization Practices regarding yellow fever vaccine. Discussion on urban yellow fever and jungle yellow fever; Vaccination for international travel; Simultaneous administration of live virus vaccines.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics